The post Vertex Stock Flashes Buy Signal; Gene-Editing Play Leads 5 Resilient Stocks In Bear Market appeared on BitcoinEthereumNews.com . Gene-editing company Vertex Pharmaceuticals (VRTX) and entertainment giant WWE (WWE) lead the five stocks to watch for the week ahead. Cardinal Health (CAH), Cameco (CCJ) and Carlisle (CSL) round out…
The Dow Jones Industrial Average powered higher as yields plunged. A Cathie Wood buy surged as Biogen (BIIB) exploded higher. Coinbase (COIN) and Riot Blockchain (RIOT) jumped as Bitcoin rose. Apple (AAPL) dived on iPhone 14 demand worries. Meanwhile, some noteworthy leaders made bullish moves. Vertex Pharmaceuticals (VRTX) and Cardinal Health (CAH) passed aggressive buy […] The post Dow Jones Jumps As Yields Plunge; This New Cathie Wood Buy Rockets; Bitcoin Rallies, Coinbase Jumps| Investor’s Business Daily appeared first on TECHTELEGRAPH .
Cardinal Health Inc. (NYSE:CAH) price closed higher on Tuesday, September 27, jumping 0.67% above its previous close. A look at the daily price movement shows that the last close reads $65.77, with intraday deals fluctuated between $65.53 and $67.32. The company’s 5Y monthly beta was ticking 0.83. Taking into account the 52-week price action we … Cardinal Health Inc. (NYSE: CAH) Could Pass $80.00 In One Year Stock Forecast Read More »
We’re in the midst of a bear market. That’s something investors haven’t seen in quite some time. While many stocks are getting crushed, it does create an opportunity for patient buyers, especially with top blue-chip stocks to buy. While some may say it’s irresponsible to buy in an environment like this, I think it’s irresponsible for long-term investors not to be buying. At the very least, investors should be putting together a list of stocks they want to own and at what price they want to own them at. I’ve been doing just that, accumulating a list of companies that have high-quality businesses but have seen their stock price come under pressure. In fact, let’s look at some blue-chip stocks to buy that are tapping into a hidden bull market. Or, at least a bull market that’s flying under the radar. JNJ Johnson & Johnson $165.54 CAH Cardinal Health $66.02 ENPH Enphase Energy $290.04 Johnson & Johnson (JNJ) Source: Sisacorn / Shutterstock.com Johnson & Johnson (NYSE: JNJ ) is one of the top blue-chip stocks to buy.
Cardinal Health''s mighty pharmaceutical sector outshines its troubled medical business. Click here to see why I label CAH as a hold.
In this article, we discuss 5 dividend stocks that raised their dividends in 2022. If you want to read our detailed discussion on dividend stocks as well as the risk/reward and methodology of this list, go directly to read 10 Dividend Stocks That Raised Their Dividends in 2022. 5. Cardinal Health, Inc. (NYSE:CAH) Number of […]
Some of the key players profiled in the study are Allianz, AXA, Nippon Life Insurance, American Intl. Group, Aviva, Assicurazioni Generali, Cardinal Health, State Farm Insurance, Dai-ichi Mutual Life Insurance, Munich Re Group, Zurich Financial Services, Prudential, Asahi Mutual Life Insurance, Sumitomo Life Insurance, MetLife, Allstate, Aegon, Prudential…
CHARLESTON, W.Va. (AP) — Walmart and CVS Pharmacy have settled with the state of West Virginia for a combined total of $147 million in a lawsuit over the companies’ roles in contributing to the oversupply of prescription drugs that fueled the opioid epidemic in the country’s most impacted state, Attorney General Patrick Morrisey announced Tuesday. Walmart and CVS were two lawsuits that were part of a larger trial that was pushed back to June of next year along with Kroger and Walgreens. Morrisey recently announced a settlement with Rite Aid for up to $30 million to resolve similar litigation. The lawsuits allege the pharmacies’ contributions to the oversupply of prescription opioids in the state have caused “significant losses through their past and ongoing medical treatment costs, including for minors born addicted to opioids, rehabilitation costs, naloxone costs, medical examiner expenses, self-funded state insurance costs and other forms of losses to address opioid-related afflictions and loss of lives.” It brings the total settlements by the state in opioid lawsuits to $875 million, including $296 million with manufacturers, $400 million with wholesalers and $177.5 million involving pharmacies. “These settlements won’t bring back the lives lost from the opioid epidemic, but these and other settlements will hopefully provide significant help to those affected the most by this crisis in our state,” Morrisey said during a news conference. “This development also avoided a costly and lengthy trial and at the end of the day, West Virginia will have the highest per capita settlement results in the nation fighting for our people.” Walmart agreed to a settlement of just over $65 million and CVS for $82.5 million.
During the recent session, Cardinal Health Inc. (NYSE:CAH)’s traded shares were 1.06 million, with the beta value of the company hitting 0.78. At the last check today, the stock’s price was $66.61, reflecting an intraday gain of 0.33% or $0.22. The 52-week high for the CAH share is $72.28, that puts it down -8.51 from … Is Cardinal Health Inc. (NYSE: CAH) Stock On Course For Another Boom Or Bust? Read More »
New Jersey, USA -- ( SBWIRE ) -- 09/15/2022 -- The latest study released on the Global Child Insurance Market by AMA Research evaluates market size, trend, and forecast to 2027. The Child Insurance market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/36305-global-child-insurance-market Key Players in This Report Include: AXA (France), Nippon Life Insurance (India), American Intl. Group (United States), Aviva (United Kingdom), Assicurazioni Generali (Italy), Cardinal Health (United States), State Farm Insurance (United States), Dai-ichi Mutual Life Insurance (China), Munich Re Group (Germany), Zurich Financial Services (Switzerland), Definition: The increasing concern related to child health safety and security will help to boost the global Child Insurance market in the forecasted period. there are various types of insurance which include security for child health, future safety, and many others.
PayrHealth said it had collaboration with Cardinal Health (CAH) to help specialty physician practices simplify payor contracting and maximize financial performance.The solutions will…
Child Health Insurance Market Analysis & Forecast for Next 5 Years New Jersey, NJ -- ( SBWIRE ) -- 09/14/2022 -- A new intelligence report released by HTF MI with title "Child Health Insurance Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Child Health Insurance offers energetic visions to conclude market size, opportunities, growth pattern, and competitive surroundings. The research is derived through primary and secondary sourced data and includes both qualitative and quantitative detailing. Some of the key players profiled in the study are Allianz, AXA, Nippon Life Insurance, American Intl. Group, Aviva, Assicurazioni Generali, Cardinal Health, State Farm Insurance, Dai-ichi Mutual Life Insurance, Munich Re Group, Zurich Financial Services, Prudential, Asahi Mutual Life Insurance, Sumitomo Life Insurance, MetLife, Allstate, Aegon, Prudential Financial, New York Life Insurance, Meiji Life Insurance, Aetna, TIAA-CREF, Mitsui Mutual Life Insurance, Royal & Sun Alliance, Swiss Reinsurance, CNP Assurances, CPIC, PingAn, Mass.
The trading price of Cardinal Health Inc. (NYSE:CAH) closed lower on Tuesday, September 13, closing at $66.83, -3.19% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $66.65 and $68.65. In examining the 52-week price action we see that the stock hit a 52-week … At What Point In Time Would I Choose To Purchase Cardinal Health Inc. (NYSE: CAH) Stock? Read More »
The following slide deck was published by Cardinal Health, Inc.
Cardinal Health Inc. cut its fiscal first-quarter earnings outlook for its Medical segment, citing ongoing simplification efforts that are expected to result in $25 million in inventory charges related to its gloves portfolio. The company now expects a Medical segment loss of $55 million to $25 million, compared with a previous guidance range for a loss of $20 million to a profit of $20 million. The health care services and products company said the expected total charge includes the sale of certain disposable gloves that are primarily used in non-health care industries. Separately, the company affirmed its fiscal 2023 adjusted earnings-per-share outlook of $5.05 to $5.40, which surrounds the FactSet consensus of $5.27. The stock, which is still inactive in premarket trading, has run up 34.1% over the past three months, while the SPDR Health Care Select Sector ETF has gained 8.0% and the S&P 500 has rallied 9.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.
Cardinal Health, Inc. (CAH) stock has jumped lately, rising 13.1% in the last month.
Cardinal Health recently entered an agreement with Elliott Management, agreeing to appoint four director nominees to the board.
Cardinal Health Inc. (NYSE:CAH) marked $70.63 per share on Thursday, down from a previous closing price of $70.97. While Cardinal Health Inc. has underperformed by -0.48%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CAH rose by 32.04%, with highs and lows ranging from $72.28 to […]
Drug distributor Cardinal Health (CAH) announced Thursday that Debbie Weitzman, current President of its Pharmaceutical Distribution, will become the Chief Executive of its…
The global "Vascular Closure Device Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Vascular Closure Device market report highlight the
WASHINGTON (dpa-AFX) - Cardinal Health (CAH) announced initiatives aimed at positioning the company for long-term success. The company said these initiatives have benefited from input received fro…
Healthcare distributor Cardinal Health, Inc. (CAH) announced several initiatives for shareholder value creation and changes to the company''s board on Tuesday with input from…
100% technical buy signals. 10 new highs and up 18.24% in the last month. 40,570 investors are monitoring the stock on Seeking Alpha.
CONCORD, N.H. (AP) — Drugmaker Johnson & Johnson has agreed to pay $40.5 million in a settlement with New Hampshire over its role in the opioid addiction crisis, days before the case was scheduled for trial, the state attorney general’s office said Thursday. The state filed a lawsuit against Johnson & Johnson and a subsidiary in 2018, alleging that they aggressively marketed their opioids to prescribers and patients in New Hampshire and misrepresented that their opioids were safer than other alternatives. The lawsuit also alleged that Johnson & Johnson made misleading statements about opioids; misrepresented that its opioids were rarely addictive when used for chronic pain; and targeted vulnerable populations, such as the elderly. “This resolution provides a positive step forward in ensuring these devastating business practices are not repeated, and that resources are allocated to help stem the tide of the opioid crisis,” Gov. Chris Sununu said in a statement. Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., denied the state’s claims, saying it truthfully marketed its prescription opioids, which accounted for a small share of the opioid medications prescribed in New Hampshire, complied with all applicable laws and regulations, did not cause the harm alleged by the state. “This settlement is not an admission of liability or wrongdoing and marks continued progress in resolving opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States,” Johnson & Johnson said in a statement. “The Company will continue to defend against any litigation that the final agreement does not resolve.” New Hampshire was one of a few states that did not join a national settlement with the company in February because its opioid crisis was “particularly severe” and because the state had already devoted “significant litigation resources” in preparation for trial, the attorney general office’s news release said.
Cardinal Health Inc. (CAH)’s stock has witnessed a price hike of 1.22% from the previous close with its current price standing at $70.69. Its current price is -1.06% under its 52-week high of $71.45 and 54.19% more than its 52-week low of $45.85. Based on the past 30-day period, the stock price is -1.61% below […]
Cardinal Health Inc. (NYSE:CAH) traded at $70.39 at last check on Wednesday, August 31, made an upward move of 0.78% on its previous day’s price. Looking at the stock we see that its previous close was $69.84 and the beta (5Y monthly) reads 0.83 with the day’s price range being $69.22 – $70.57. In terms … What Did We Find About Insider Trading At Cardinal Health Inc. (NYSE: CAH)? Read More »
Related Stocks: EMBC , MCK , CAH , REGN , ENTA ,
https://www.investing.com/news/stock-market-news/cardinal-health-upside-elusive-says-analyst-following-elliott-management-reports-432SI-2873983
The apparent large stake from activist investor Elliott Management in Cardinal Health (CAH) could help catalyze focus on margin improvements and unlocking value in the Medical segment.
Wholesale drug distributors Cardinal Health (CAH) and McKesson both hit 52-week highs today of, respectively, $71.45 and $371.92.
Activist investor Elliott Management has a large position in Cardinal Health Inc and is seeking a few seats on the medical products distributor’s board, the Wall Street Journal reported on Monday, citing people familiar with the matter. Elliott nominated five directors to the 11-person board roughly two weeks ago, before Mike Kaufmann stepped down as […]
According to Benzinga Pro, during Q4, Cardinal Health (NYSE: CAH ) earned $137.00 million, a 109.86% increase from the preceding quarter. Cardinal Health also posted a total of $47.10 billion in sales, a 5.06% increase since Q3. In Q3, Cardinal Health brought in $44.84 billion in sales but lost $1.39 billion in earnings. What Is ROIC? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company''s ROIC. A higher ROIC is generally representative of successful growth … Full story available on Benzinga.com
Cardinal Health Inc. (NYSE: CAH) Q4 2022 earnings call dated Aug. 11, 2022 Corporate Participants: Kevin Moran — Vice President of Investor Relations Mike Kaufmann — Chief Executive Officer Jason Hollar — Chief Financial Officer Analysts: […] The post Cardinal Health Inc. (CAH) Q4 2022 Earnings Call Transcript first appeared on AlphaStreet .
Cardinal Health Inc. (NYSE: CAH) Q4 2022 earnings call dated Aug. 11, 2022
Cardinal Health, Inc. (NYSE:NYSE:CAH) Q4 2022 Earnings Conference Call August 11, 2022, 08:30 ET Company Participants Kevin Moran - VP, IR Michael Kaufmann - CEO & Director Jason Hollar…
Third Annual Award Program Powered by Peer Voting Recognizes Heroes for Ability to Respond to IT Inc BigPanda, the leader in AIOps Event Correlation and Automation, and online incident management academy Blackrock 3 Partners, announced the winners of the 2022 Incident Commander Awards, a peer-voted award program honoring IT rockstars in support, ITOps, DevOps, SRE […] The post BigPanda and Blackrock 3 Partners Honor Incident Commanders from Cardinal Health, Milestone Technologies, OneMain Financial and Sony PlayStation appeared first on AiThority .
Cardinal Health (CAH) is scheduled to announce Q4 earnings results on Thursday, August 11th, before market open.The consensus EPS Estimate is $1.18 (+53.2% Y/Y) and the consensus…
New Jersey, USA -- ( SBWIRE ) -- 08/08/2022 -- The latest study released on the Global Interventional Radiology Devices Market by AMA Research evaluates market size, trend, and forecast to 2027. The Interventional Radiology Devices market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players in This Report Include: Abbott (United States), B. Braun (Germany), Boston Scientific (United States), Koninklijke Philips (Netherlands), Cardinal Health (United States), Medtronic (Ireland), Alvimedica (Turkey), Guerbet (France), Angiodynamics (United States), Balton (Poland) and Brosmed Medical (China). Additionally, following companies can also be profiled that are part of our coverage like Biosensors (Switzerland), Biotronik (Germany), Cook Medical (United States) and Endocor (Germany) Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/78326-global-interventional-radiology-devices-market Definition: Image-guided surgery seems to be what interventional radiology is all about.
The Labor Department issues its second-quarter snapshot of U.S. employee productivity Tuesday and its latest monthly index of inflation at the consumer level Wednesday
Tennessee’s attorney general said Wednesday he has sued Walgreens, accusing the drugstore chain of contributing to the state’s opioid crisis by failing to maintain effective controls against the abuse of prescription pain pills. The lawsuit seeking unspecified civil penalties was filed in Knox County Circuit Court by Attorney General Herbert H. Slatery III and alleges violations of Tennessee’s Consumer Protection Act. The lawsuit said that between 2006 and 2020, Walgreens retail stores in Tennessee dispensed more than 1.1 billion oxycodone and hydrocodone pills. One pharmacy alone in Jamestown dispensed enough opioids over that period to supply each resident with 2,104 pills. “Walgreens did not flood the State of Tennessee with opioids by accident,” Slatery said in a statement. “Rather, the fuel that Walgreens added to the fire of the opioid epidemic was the result of knowing — or willfully ignorant — corporate decisions. Walgreens ignored numerous red flags and failed to detect and prevent the abuse and diversion of dangerous narcotics.” Walgreens did not offer immediate comment Wednesday.
Some of the key players profiled in the study are Caisse Nationale de Prevoyance, Samsung Life Insurance, Berkshire Hathaway, State Farm Insurance, AXA, Sumitomo Life Insurance, China Ping An Insurance Co., Ltd., China Life Insurance Company, Japan Post Holdings Co., Ltd., Cardinal Health, PICC, Nippon Life Insurance, Botswana Insurance Company, Munich Re Group,…
Edison, NJ -- ( SBWIRE ) -- 08/02/2022 -- Advance Market Analytics published a new research publication on "Latex Chemical Protective Glove Market Insights, to 2027" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Latex Chemical Protective Glove market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/200208-global-latex-chemical-protective-glove-market#utm_source=SBWireLal Some of the key players profiled in the study are: Ansell Healthcare (United States), Cardinal Health (United States), Top Glove Corporation Bhd (Malaysia), Supermax Corporation Berhad (Malaysia), Clean Q Grip (Malaysia), SHIELD Scientific (The Netherlands), UG Healthcare (Malaysia), Valutek (United States), 3M Company (United States) and DuPont (United States).
Botswana Insurance Market 2022-2028 Edison, NJ -- ( SBWIRE ) -- 08/02/2022 -- 2022-2030 World Botswana Insurance Market Report Professional Analysis 2022 is latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Botswana Insurance Market. Some of the key players profiled in the study are Caisse Nationale de Prevoyance, Samsung Life Insurance, Berkshire Hathaway, State Farm Insurance, AXA, Sumitomo Life Insurance, China Ping An Insurance (Group) Co., Ltd., China Life Insurance (Group) Company, Japan Post Holdings Co., Ltd., Cardinal Health, PICC, Nippon Life Insurance, Botswana Insurance Company, Munich Re Group, Asahi Mutual Life Insurance, MetLife Inc., AVIVA, Aegon, American International Group, Allianz, UK Legal and General, Assicurazioni General, Zurich Financial Services, The Dai-ichi Life Insurance Company, Limited & Prudential.
Related Stocks: MMM , CLX , CONE , CAH , KMB ,
CHARLESTON, W.Va. (AP) — West Virginia cities and counties reached a $400 million tentative settlement with three major U.S. drug distributors, lawyers announced Monday. In a lawsuit in state court, the cities and counties accused the distributors of fueling the opioid epidemic. The companies are AmerisourceBergen, Cardinal Health and McKesson. The funds will be distributed over 12 years. “This is a monumental settlement for the state of West Virginia, and it’s been a battle that’s been waged by a lot of families, a lot of communities,” Wheeling attorney Bob Fitzsimmons told news outlets. “A lot of bad things have happened as a result of the opioid epidemic.” Fitzsimmons and Huntington attorney Paul Farrell Jr. said the individual counties and municipalities still must approve the settlement. Lauren Esposito, vice president of external and executive communications for AmerisourceBergen, said the settlement will avoid years of litigation and help get resources to areas affected by opioid misuse, as well as make sure health care facilities are able to access medications that patients and providers need, news outlets reported.
Three leading drug distributors in the U.S., McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH), have struck a $400M settlement with West Virginia''s cities and counties…
West Virginia’s cities and counties reached a $400 million settlement on Monday with drug distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, resolving the local governments’ allegations that the three companies fueled an opioid crisis in the state. More than 100 local governments had sued the drug distributors, alleging they recklessly oversupplied West Virginia […]
HARRISBURG, Pa. (AP) — A former opioid manufacturer has agreed in principle to pay up to $2.4 billion in a deal with a dozen states over its marketing and product safety practices, state attorneys general announced Friday. The company, Allergan, is now part of AbbVie but sold its generics division Actavis, including its opioid products, to Teva Pharmaceuticals six years ago. Under the settlement, payments will be made to state and local governments, Pennsylvania Attorney General Josh Shapiro said. The agreement means pharma companies have consented to pay more than $40 billion to settle opioid crisis claims regarding manufacturers and distributors, The Associated Press has found. The agreement came days after a similar, $4.3 billion agreement was reached with Teva Pharmaceuticals. A message seeking comment were left Friday with a corporate spokesperson for Teva. Shapiro said the settlement involved claims that Allergan, which produced Norco and Kadian brand generic opioids, downplayed the risk of addiction in marketing and did not act sufficiently to prevent the drugs from being improperly diverted. “No amount of money will bring back the lives we lost, but today’s agreement will help ensure we can fund the programs Pennsylvania counties need for our communities to recover from this crisis,” Shapiro said in a statement.
AmerisourceBergen (NYSE: ABC ) has outperformed the market over the past 15 years by 6.21% on an annualized basis producing an average annual return of 13.0%. Currently, AmerisourceBergen has a market capitalization of $30.05 billion. Buying $1000 In ABC: If an … Full story available on Benzinga.com
AmerisourceBergen Corporation found using ticker (ABC) have now 12 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 187 and 150 with a mean TP of 170.67. Now with the previous closing price of 142.14 this is indicating there is a potential upside of 20.1%. The day 50 moving average is 146.35 and the 200 day MA is 139.47. The market capitalisation for the company is $29,849m. You can visit the company''s website by visiting: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $35,840m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
https://www.investing.com/news/pro/amerisourcebergen-pt-raised-to-170-at-argus-432SI-2849541
AmerisourceBergen Corporation found using ticker (ABC) now have 12 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 187 and 150 with a mean TP of 170.67. Given that the stocks previous close was at 139.53 this would indicate that there is a potential upside of 22.3%. The 50 day MA is 147.92 and the 200 moving average now moves to 138.92. The market cap for the company is $29,790m. Company Website: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,438m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
Sometimes Stocks Move Fast, and Amerisourcebergen ABC is no Exception
SAN FRANCISCO (AP) — Opioid makers Allergan and Teva have agreed to pay $54 million in cash and overdose reversal drugs to settle a federal lawsuit brought by San Francisco alleging the drug industry fueled an overdose and addiction surge that created a public nuisance. City Attorney David Chiu made the announcement with closing arguments against the sole remaining defendant, Walgreens, scheduled to begin Tuesday. The lawsuit alleges that the pharmacy chain over-dispensed opioids without proper oversight and failed to identify and report suspicious orders as required by law. The agreement announced Tuesday calls for the two opioid manufacturers to pay San Francisco $34 million in cash and provide $20 million worth of the overdose reversal drug, Narcan. The San Francisco case is one of only a handful of government claims against companies over the opioid epidemic so far that have gone to trial. More cases have settled before trials. Earlier this year, the distribution companies AmerisourceBergen, Cardinal Health and McKesson plus drug maker Johnson & Johnson finalized nationwide settlements totaling $26 billion .
Evercore ISI has downgraded AmerisourceBergen (ABC) to in line from outperform citing valuation, concern on future operating performance, and Walgreens Boots Alliance May sale of shares.
AmerisourceBergen (NYSE: ABC ) has outperformed the market over the past 10 years by 2.61% on an annualized basis producing an average annual return of 13.54%. Currently, AmerisourceBergen has a market capitalization of $29.70 billion. Buying $1000 In ABC: If an … Full story available on Benzinga.com
AmerisourceBergen Corporation with ticker code (ABC) now have 12 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 187 and 155 with a mean TP of 171.92. Now with the previous closing price of 140.79 this indicates there is a potential upside of 22.1%. The 50 day MA is 149.17 and the 200 day MA is 138.45. The company has a market capitalisation of $29,859m. Company Website: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,461m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
Doctors’ ‘good faith’ prescribing decisions drove volume of painkillers shipped to pharmacies, says district judge David Faber The US’s three largest pharmaceutical distributors were not responsible for fueling an opioid epidemic in a part of West Virginia , a federal judge ruled on Monday. District judge David Faber rejected efforts by the city of Huntington and Cabell County to force McKesson, AmerisourceBergen and Cardinal Health to pay $2.5bn to address a drug crisis prompted by a flood of addictive pills in their region. Continue reading…
Reuters Norwegian Offshore Workers’ Strike To Hit Norway’s Oil & Gas Output Norwegian offshore oil and gas workers went on strike over pay after the members of the Lederne trade union voted down a proposed wage agreement that companies and union leaders had negotiated, Reuters reported. “The strike has begun,” Audun Ingvartsen, the leader of the Lederne trade union, said in an interview, adding that the union would escalate the strike to pressure employers to address demands for the wage increase. Equinor ASA (NYSE: EQNR ) has started to shut down the Gudrun, Oseberg South, and Oseberg East fields in the North Sea due to a strike. Pilot Strike Forces SAS To File For Chapter 11 Bankruptcy In US Scandinavian airline SAS AB (OTC: SASDY ) has filed for bankruptcy protection in the U.S. to help accelerate restructuring plans. Wage discussions between SAS and its pilots collapsed, sparking a strike that would add to travel disruption across Europe, Reuters reported. A strike by SAS pilots has accelerated the airline’s decision to file for Chapter 11 bankruptcy protection in the U.S., the report quoted the airline’s CEO, Anko van der Werff.